Review on immunosuppression in liver transplantation

World Journal of Hepatology

Volumn 7, Issue 10, 2015, Pages 1355-1368

  Moini, Maryam ^a   Schilsky, Michael L ^b   Tichy, Eric M ^c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b YALE UNIVERSITY MEDICAL CENTER   (United States)

^c YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

Immunosuppression; Immunosuppression induction; Immunosuppression maintenance; Liver transplantation

Indexed keywords

EID: 84930408583     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i10.1355     Document Type: Review

References (118)

1. Adam R, Hoti E. Liver transplantation: the current situation. Semin Liver Dis 2009; 29: 3-18 [PMID: 19235656 DOI: 10.1055/s-0029-1192052].
2. Crispe IN. Immune tolerance in liver disease. Hepatology 2014; 60: 2109-2117 [PMID: 24913836 DOI: 10.1002/hep.27254].
3. Crispe IN, Giannandrea M, Klein I, John B, Sampson B, Wuensch S. Cellular and molecular mechanisms of liver tolerance. Immunol Rev 2006; 213: 101-118 [PMID: 16972899 DOI: 10.1111/j.1600-065X.2006.00435.x].
4. Opelz G, Wujciak T, Döhler B, Scherer S, Mytilineos J. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet 1999; 1: 334-342 [PMID: 11256424].
5. Opelz G, Margreiter R, Döhler B. Prolongation of long-term kidney graft survival by a simultaneous liver transplant: the liver does it, and the heart does it too. Transplantation 2002; 74: 1390-1394; discussion 1370-1371 [PMID: 12451237 DOI: 10.1097/01. TP.0000034923.37376.9F].
6. Raichlin E, Daly RC, Rosen CB, McGregor CG, Charlton MR, Frantz RP, Clavell AL, Rodeheffer RJ, Pereira NL, Kremers WK, Kushwaha SS, Edwards BS. Combined heart and liver transplantation: a single-center experience. Transplantation 2009; 88: 219-225 [PMID: 19623017 DOI: 10.1097/TP. 0b013e3181ac60 db].
7. Rana A, Robles S, Russo MJ, Halazun KJ, Woodland DC, Witkowski P, Ratner LE, Hardy MA. The combined organ effect: protection against rejection?. Ann Surg 2008; 248: 871-879 [PMID: 18948817 DOI: 10.1097/SLA.0b013e31817fc2b8].
8. de la Garza RG, Sarobe P, Merino J, Lasarte JJ, D'Avola D, Belsue V, Delgado JA, Silva L, Iñarrairaegui M, Sangro B, Sola JJ, Pardo F, Quiroga J, Herrero JI. Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl 2013; 19: 937-944 [PMID: 23784747 DOI: 10.1002/lt.23686].
9. Fisher RA, Cotterell AH, Maluf DG, Stravitz RT, Ashworth A, Nakatsuka M, Sterling RK, Luketic VA, Behnke MK, Posner MP. Adult living donor versus deceased donor liver transplantation: a 10-year prospective single center experience. Ann Hepatol 2009; 8: 298-307 [PMID: 20009128].
10. Maluf DG, Stravitz RT, Cotterell AH, Posner MP, Nakatsuka M, Sterling RK, Luketic VA, Shiffman ML, Ham JM, Marcos A, Behnke MK, Fisher RA. Adult living donor versus deceased donor liver transplantation: a 6-year single center experience. Am J Transplant 2005; 5: 149-156 [PMID: 15636624 DOI: 10.1111/j.1600-6143.2004.00654.x].
11. Shaked A, Ghobrial RM, Merion RM, Shearon TH, Emond JC, Fair JH, Fisher RA, Kulik LM, Pruett TL, Terrault NA. Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation. Am J Transplant 2009; 9: 301-308 [PMID: 19120082 DOI: 10.1111/j.1600-6143.2008.02487.x].
12. Sieders E, Hepkema BG, Peeters PM, TenVergert EM, de Jong KP, Porte RJ, Bijleveld CM, van den Berg AP, Lems SP, Gouw AS, Slooff MJ. The effect of HLA mismatches, shared cross-reactive antigen groups, and shared HLA-DR antigens on the outcome after pediatric liver transplantation. Liver Transpl 2005; 11: 1541-1549 [PMID: 16315307 DOI: 10.1002/lt.20521].
13. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963; 117: 659-676 [PMID: 14100514].
14. Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, Alonso EM, Philogene MC, Ikle D, Poole KM, Bridges ND, Turka LA, Tchao NK. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307: 283-293 [PMID: 22253395 DOI: 10.1001/jama.2011.2014].
15. Kirk AD. Induction immunosuppression. Transplantation 2006; 82: 593-602 [PMID: 16969280 DOI: 10.1097/01.tp.0000234905.56926.7f].
16. Starzl TE, Marchioro TL, Waddell WR. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 1963; 117: 385-395 [PMID: 14065716].
17. Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl 2004; 10: 728-733 [PMID: 15162466 DOI: 10.1002/lt.20144].
18. Bush WW. Overview of transplantation immunology and the pharmacotherapy of adult solid organ transplant recipients: focus on immunosuppression. AACN Clin Issues 1999; 10: 253-269; quiz 304-306 [PMID: 10578712].
19. Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C, Hudson S, Bynon JS. The safety and efficacy of a twodose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation 2000; 69: 1867-1872 [PMID: 10830224].
20. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161-165 [PMID: 9428817 DOI: 10.1056/NEJM199801153380304].
21. Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N, Nishida S, Moon J, Selvaggi G, Levi D, Ruiz P, Schiff E, Tzakis A. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007; 84: 829-835 [PMID: 17984834 DOI: 10.1097/01.tp.0000282914.20578.7b].
22. Lupo L, Panzera P, Tandoi F, Carbotta G, Giannelli G, Santantonio T, Rendina M, Gentile A, Memeo V. Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial. Transplantation 2008; 86: 925-931 [PMID: 18852657 DOI: 10.1097/TP.0b013e318186b8a3].
23. Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C. Antibody induction versus corticosteroid induction for liver transplant recipients. Cochrane Database Syst Rev 2014; 5: CD010252 [PMID: 24880007 DOI: 10.1002/14651858.CD010252. pub2].
24. Beckebaum S, Cicinnati VR, Radtke A, Kabar I. Calcineurin inhibitors in liver transplantation-still champions or threatened by serious competitors?. Liver Int 2013; 33: 656-665 [PMID: 23442173 DOI: 10.1111/liv.12133].
25. Kaden J, Völp A, Wesslau C. High graft protection and low incidences of infections, malignancies and other adverse effects with intra-operative high dose ATG-induction: a single centre cohort study of 760 cases. Ann Transplant 2013; 18: 9-22 [PMID: 23792496 DOI: 10.12659/AOT.883792].
26. Gotthardt DN, Bruns H, Weiss KH, Schemmer P. Current strategies for immunosuppression following liver transplantation. Langenbecks Arch Surg 2014; 399: 981-988 [PMID: 24748543 DOI: 10.1007/s00423-014-1191-9].
27. Bijleveld CG, Klompmaker IJ, van den Berg AP, Gouw AS, Hepkema BG, Haagsma EB, Verwer R, Slooff MJ. Incidence, risk factors, and outcome of antithymocyte globulin treatment of steroid-resistant rejection after liver transplantation. Transpl Int 1996; 9: 570-575 [PMID: 8914237].
28. Schmitt TM, Phillips M, Sawyer RG, Northup P, Hagspiel KD, Pruett TL, Bonatti HJ. Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation. Dig Dis Sci 2010; 55: 3224-3234 [PMID: 20238251 DOI: 10.1007/s10620-010-1149-x].
29. Langrehr JM, Nüssler NC, Neumann U, Guckelberger O, Lohmann R, Radtke A, Jonas S, Klupp J, Steinmüller T, Lobeck H, Meuer S, Schlag H, Lemmens HP, Knoop M, Keck H, Bechstein WO, Neuhaus P. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation. Transplantation 1997; 63: 1772-1781 [PMID: 9210503].
30. Benítez CE, Puig-Pey I, López M, Martínez-Llordella M, Lozano JJ, Bohne F, Londoño MC, García-Valdecasas JC, Bruguera M, Navasa M, Rimola A, Sánchez-Fueyo A. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant 2010; 10: 2296-2304 [PMID: 20883560 DOI: 10.1111/j.1600-6143.2010.03164.x].
31. Deeks ED, Keating GM. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs 2009; 69: 1483-1512 [PMID: 19634926 DOI: 10.2165/00003495-200969110-00007].
32. Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, Dolan S, Kano JM, Mahon M, Schnitzler MA, Woodward R, Irish W, Singer GG. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011-1018 [PMID: 10221486].
33. Soliman T, Hetz H, Burghuber C, Györi G, Silberhumer G, Steininger R, Mühlbacher F, Berlakovich GA. Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation. Transpl Int 2007; 20: 447-452 [PMID: 17343686 DOI: 10.1111/j.1432-2277.2007.00463.x].
34. Mangus RS, Fridell JA, Vianna RM, Kwo PY, Chen J, Tector AJ. Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up. Liver Transpl 2012; 18: 786-795 [PMID: 22237953 DOI: 10.1002/lt.23381].
35. Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002; 73: 1514-1518 [PMID: 12023634].
36. Busani S, Rinaldi L, Begliomini B, Pasetto A, Girardis M. Thymoglobulin-induced severe cardiovascular reaction and acute renal failure in a patient scheduled for orthotopic liver transplantation. Minerva Anestesiol 2006; 72: 243-248 [PMID: 16570036].
37. Lundquist AL, Chari RS, Wood JH, Miller GG, Schaefer HM, Raiford DS, Wright KJ, Gorden DL. Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl 2007; 13: 647-650 [PMID: 17377915 DOI: 10.1002/lt.21098].
38. Soliman T, Hetz H, Burghuber C, Györi G, Silberhumer G, Steininger R, Mühlbacher F, Berlakovich GA. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl 2007; 13: 1039-1044 [PMID: 17600336 DOI: 10.1002/lt.21185].
39. Eason JD, Blazek J, Mason A, Nair S, Loss GE. Steroid-free immunosuppression through thymoglobulin induction in liver transplantation. Transplant Proc 2001; 33: 1470-1471 [PMID: 11267378].
40. Garcia-Saenz-de-Sicilia M, Olivera-Martinez MA, Grant WJ, Mercer DF, Baojjang C, Langnas A, McCashland T. Impact of anti-thymocyte globulin during immunosuppression induction in patients with hepatitis C after liver transplantation. Dig Dis Sci 2014; 59: 2804-2812 [PMID: 24865255 DOI: 10.1007/s10620-014-3215-2].
41. De Ruvo N, Cucchetti A, Lauro A, Masetti M, Cautero N, Di Benedetto F, Dazzi A, Del Gaudio M, Ravaioli M, Zanello M, La Barba G, di Francesco F, Risaliti A, Ramacciato G, Pinna AD. Preliminary results of immunosuppression with thymoglobuline pretreatment and hepatitis C virus recurrence in liver transplantation. Transplant Proc 2005; 37: 2607-2608 [PMID: 16182760 DOI: 10.1016/j.transproceed.2005.06.070].
42. Marks WH, Ilsley JN, Dharnidharka VR. Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review. Transplant Proc 2011; 43: 1395-1404 [PMID: 21693205 DOI: 10.1016/j.transproceed.2011.03.036].
43. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006; 19: 705-714 [PMID: 16918530 DOI: 10.1111/j.1432-2277.2006.00343.x].
44. Dhesi S, Boland B, Colquhoun S. Alemtuzumab and liver transplantation: a review. Curr Opin Organ Transplant 2009; 14: 245-249 [PMID: 19417659 DOI: 10.1097/MOT. 0b013e32832b45d 0].
45. Tzakis AG, Tryphonopoulos P, Kato T, Nishida S, Levi DM, Madariaga JR, Gaynor JJ, De Faria W, Regev A, Esquenazi V, Weppler D, Ruiz P, Miller J. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004; 77: 1209-1214 [PMID: 15114087].
46. Levitsky J, Thudi K, Ison MG, Wang E, Abecassis M. Alemtuzumab induction in non-hepatitis C positive liver transplant recipients. Liver Transpl 2011; 17: 32-37 [PMID: 21254342 DOI: 10.1002/lt.22180].
47. Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, Devera M, Marsh W, Gayowski T, Demetris AJ, Gray EA, Flynn B, Zeevi A, Murase N, Starzl TE. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004; 78: 966-971 [PMID: 15480160].
48. Mukherjee S, Mukherjee U. A comprehensive review of immunosuppression used for liver transplantation. J Transplant 2009; 2009: 701464 [PMID: 20130772 DOI: 10.1155/2009/701464].
49. Uemura T, Schaefer E, Hollenbeak CS, Khan A, Kadry Z. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid. Transpl Int 2011; 24: 640-650 [PMID: 21429047 DOI: 10.1111/j.1432-2277.2011.01250.x].
50. Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011; 17: 1394-1403 [PMID: 21850690 DOI: 10.1002/lt.22417].
51. Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months. Transplant Proc 2006; 38: 3633-3635 [PMID: 17175352 DOI: 10.1016/j.transproceed.2006.10.110].
52. Iwatsuki S, Starzl TE, Todo S, Gordon RD, Esquivel CO, Tzakis AG, Makowka L, Marsh JW, Koneru B, Stieber A. Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc 1988; 20: 498-504 [PMID: 3279643].
53. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006; (4): CD005161 [PMID: 17054241 DOI: 10.1002/14651858.CD005161.pub2].
54. Rodríguez-Perálvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2012; 12: 2797-2814 [PMID: 22703529 DOI: 10.1111/j.1600-6143.2012.04140.x].
55. Villamil F, Pollard S. C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician's perspective. Liver Transpl 2004; 10: 577-583 [PMID: 15108248 DOI: 10.1002/lt.20112].
56. Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol 2013; 37: 602-612 [PMID: 23796509 DOI: 10.1159/000351648].
57. Doesch AO, Müller S, Konstandin M, Celik S, Kristen A, Frankenstein L, Ehlermann P, Sack FU, Katus HA, Dengler TJ. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal. Transplant Proc 2010; 42: 3694-3699 [PMID: 21094840 DOI: 10.1016/j.transproce ed.2010.07.107].
58. Berardinelli L, Messa PG, Pozzoli E, Beretta C, Montagnino G. Malignancies in 2,753 kidney recipients transplanted during a 39-year experience. Transplant Proc 2009; 41: 1231-1232 [PMID: 19460526 DOI: 10.1016/j.transproceed.2009.03.032].
59. Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol 2014; 88: 1351-1389 [PMID: 24792322 DOI: 10.1111/j. 1432-2277.2011.01250. x].
60. Kim WR, Smith JM, Skeans MA, Schladt DP, Schnitzler MA, Edwards EB, Harper AM, Wainright JL, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2012 Annual Data Report: liver. Am J Transplant 2014; 14 Suppl 1: 69-96 [PMID: 24373168 DOI: 10.1111/ajt.12581].
61. Parfitt JR, Jayakumar S, Driman DK. Mycophenolate mofetilrelated gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes. Am J Surg Pathol 2008; 32: 1367-1372 [PMID: 18763324].
62. Al-Absi AI, Cooke CR, Wall BM, Sylvestre P, Ismail MK, Mya M. Patterns of injury in mycophenolate mofetil-related colitis. Transplant Proc 2010; 42: 3591-3593 [PMID: 21094821 DOI: 10.1016/j.transproceed.2010.08.066].
63. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954-2960 [PMID: 16303010 DOI: 10.1111/j.1600-6143.2005.01125.x].
64. Rodríguez-Perálvarez M, De la Mata M, Burroughs AK. Liver transplantation: immunosuppression and oncology. Curr Opin Organ Transplant 2014; 19: 253-260 [PMID: 24685671 DOI: 10.1097/MOT.0000000000000069].
65. Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J Clin Pathol 2010; 63: 288-295 [PMID: 20354201 DOI: 10.1136/jcp.2009.069252].
66. Shenoy S, Hardinger KL, Crippin J, Desai N, Korenblat K, Lisker-Melman M, Lowell JA, Chapman W. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. Transplantation 2007; 83: 1389-1392 [PMID: 17519792 DOI: 10.1097/01.tp.0000261630.63550.41].
67. Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E, Neff GW, Ranjan D, Toselli LT, Gane EJ, Scarola J, Alberts RG, Maller ES, Lo CM. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant 2012; 12: 694-705 [PMID: 22233522 DOI: 10.1111/j.1600-6143.2011.03919.x].
68. Asrani SK, Wiesner RH, Trotter JF, Klintmalm G, Katz E, Maller E, Roberts J, Kneteman N, Teperman L, Fung JJ, Millis JM. De novo sirolimus and reduced-dose tacrolimus versus standarddose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant 2014; 14: 356-366 [PMID: 24456026 DOI: 10.1111/ajt.12543].
69. Saliba F, De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Jonas S, Sudan D, Fischer L, Duvoux C, Chavin KD, Koneru B, Huang MA, Chapman WC, Foltys D, Dong G, Lopez PM, Fung J, Junge G. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant 2013; 13: 1734-1745 [PMID: 23714399 DOI: 10.1111/ajt.12280].
70. Finn RS. Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer 2012; 1: 247-256 [PMID: 24159589 DOI: 10.1159/000343839].
71. Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013; 37: 411-419 [PMID: 23278125 DOI: 10.1111/apt.12185].
72. Jeng LB, Thorat A, Hsieh YW, Yang HR, Yeh CC, Chen TH, Hsu SC, Hsu CH. Experience of using everolimus in the early stage of living donor liver transplantation. Transplant Proc 2014; 46: 744-748 [PMID: 24767339 DOI: 10.1016/j.transproceed.2013.11.0 68].
73. Wadei HM, Zaky ZS, Keaveny AP, Rosser B, Jones M, Mai ML, Bulatao I, Gonwa TA. Proteinuria following sirolimus conversion is associated with deterioration of kidney function in liver transplant recipients. Transplantation 2012; 93: 1006-1012 [PMID: 22357174 DOI: 10.1097/TP.0b013e31824bbd01].
74. Das BB, Shoemaker L, Subramanian S, Johnsrude C, Recto M, Austin EH. Acute sirolimus pulmonary toxicity in an infant heart transplant recipient: case report and literature review. J Heart Lung Transplant 2007; 26: 296-298 [PMID: 17346635 DOI: 10.1016/j.healun.2006.12.004].
75. Amigues L, Klouche K, Massanet P, Gaillard N, Garrigue V, Beraud JJ, Mourad G. Sirolimus-associated acute respiratory distress syndrome in a renal transplant recipient. Transplant Proc 2005; 37: 2830-2831 [PMID: 16182823 DOI: 10.1016/j.transproce ed.2005.05.016].
76. Montalbano M, Neff GW, Yamashiki N, Meyer D, Bettiol M, Slapak-Green G, Ruiz P, Manten E, Safdar K, O'Brien C, Tzakis AG. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimusrelated complications. Transplantation 2004; 78: 264-268 [PMID: 15280688].
77. Pengel LH, Liu LQ, Morris PJ. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. Transpl Int 2011; 24: 1216-1230 [PMID: 21955006 DOI: 10.1111/j.1432-2277.2011.01357.x].
78. Molinari M, Berman K, Meeberg G, Shapiro JA, Bigam D, Trotter JF, Kneteman N. Multicentric outcome analysis of sirolimusbased immunosuppression in 252 liver transplant recipients. Transpl Int 2010; 23: 155-168 [PMID: 19765266 DOI: 10.1111/j.1432-2277.2009.00969.x].
79. Harper SJ, Gelson W, Harper IG, Alexander GJ, Gibbs P. Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: a single-center experience. Transplantation 2011; 91: 128-132 [PMID: 21452417].
80. Fischer L, Klempnauer J, Beckebaum S, Metselaar HJ, Neuhaus P, Schemmer P, Settmacher U, Heyne N, Clavien PA, Muehlbacher F, Morard I, Wolters H, Vogel W, Becker T, Sterneck M, Lehner F, Klein C, Kazemier G, Pascher A, Schmidt J, Rauchfuss F, Schnitzbauer A, Nadalin S, Hack M, Ladenburger S, Schlitt HJ. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT. Am J Transplant 2012; 12: 1855-1865 [PMID: 22494671 DOI: 10.1111/j.1600-6143.2012.04049.x].
81. Rodriguez-Luna H, Douglas DD. Natural history of hepatitis C following liver transplantation. Curr Opin Infect Dis 2004; 17: 363-371 [PMID: 15241083].
82. Joshi D, Pinzani M, Carey I, Agarwal K. Recurrent HCV after liver transplantation-mechanisms, assessment and therapy. Nat Rev Gastroenterol Hepatol 2014; 11: 710-721 [PMID: 25023032 DOI: 10.1038/nrgastro.2014.114].
83. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 Suppl 2: S36-S44 [PMID: 18825724 DOI: 10.1002/lt.21646].
84. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, Kolesnikov V, Bodenheimer H, Emre S, Miller CM. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30-34 [PMID: 7806166].
85. Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, Kurosaki M, Maekawa S, Yamashiro T, Chen CH, Itsui Y, Kakinuma S, Watanabe M. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004; 313: 42-47 [PMID: 14672695].
86. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-1288 [PMID: 14578868 DOI: 10.1053/jhep.2003.50449].
87. Hirano K, Ichikawa T, Nakao K, Matsumoto A, Miyaaki H, Shibata H, Eguchi S, Takatsuki M, Ikeda M, Yamasaki H, Kato N, Kanematsu T, Ishii N, Eguchi K. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl 2008; 14: 292-298 [PMID: 18306331 DOI: 10.1002/lt.21358].
88. Duvoux C, Firpi R, Grazi GL, Levy G, Renner E, Villamil F. Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor. Transpl Int 2013; 26: 358-372 [PMID: 23413991 DOI: 10.1111/tri.12065].
89. Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998; 66: 493-499 [PMID: 9734494].
90. Irish WD, Arcona S, Bowers D, Trotter JF. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant 2011; 11: 1676-1685 [PMID: 21564522 DOI: 10.1111/j. 1600-6143. 2011.03508.x].
91. Biecker E, De Gottardi A, Neef M, Unternährer M, Schneider V, Ledermann M, Sägesser H, Shaw S, Reichen J. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J Pharmacol Exp Ther 2005; 313: 952-961 [PMID: 15769867 DOI: 10.1124/jpet.104.079616].
92. Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006; 45: 786-796 [PMID: 17050028 DOI: 10.1016/j.jhep.2006.07.030].
93. Kelly MA, Kaplan M, Nydam T, Wachs M, Bak T, Kam I, Zimmerman MA. Sirolimus reduces the risk of significant hepatic fibrosis after liver transplantation for hepatitis C virus: a singlecenter experience. Transplant Proc 2013; 45: 3325-3328 [PMID: 24182811 DOI: 10.1016/j.transproceed.2013.04.011].
94. McKenna GJ, Trotter JF, Klintmalm E, Onaca N, Ruiz R, Jennings LW, Neri M, O'Leary JG, Davis GL, Levy MF, Goldstein RM, Klintmalm GB. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011; 11: 2379-2387 [PMID: 21967703 DOI: 10.1111/j.1600-6143.2011.03767.x].
95. Watt KD, Dierkhising R, Heimbach JK, Charlton MR. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl 2012; 18: 1029-1036 [PMID: 22641474].
96. Deshpande NA, James NT, Kucirka LM, Boyarsky BJ, Garonzik-Wang JM, Cameron AM, Singer AL, Dagher NN, Segev DL. Pregnancy outcomes of liver transplant recipients: a systematic review and meta-analysis. Liver Transpl 2012; 18: 621-629 [PMID: 22344967 DOI: 10.1002/lt.23416].
97. Parhar KS, Gibson PS, Coffin CS. Pregnancy following liver transplantation: review of outcomes and recommendations for management. Can J Gastroenterol 2012; 26: 621-626 [PMID: 22993734].
98. Christopher V, Al-Chalabi T, Richardson PD, Muiesan P, Rela M, Heaton ND, O'Grady JG, Heneghan MA. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transpl 2006; 12: 1138-1143 [PMID: 16799943 DOI: 10.1002/lt.20810].
99. Fischer-Betz R, Specker C, Brinks R, Aringer M, Schneider M. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford) 2013; 52: 1070-1076 [PMID: 23382355 DOI: 10.1093/rheumatology/kes425].
100. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006; 82: 1698-1702 [PMID: 17198262 DOI: 10.1097/01.tp.0000252683.74584.29].
101. Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O'Beirne J, Poyato-González A, Ferrín-Sánchez G, Montero-álvarez JL, Patch D, Thorburn D, Briceño J, De la Mata M, Burroughs AK. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013; 59: 1193-1199 [PMID: 23867318 DOI: 10.1016/j.jhep.2013.07.012].
102. Chen K, Man K, Metselaar HJ, Janssen HL, Peppelenbosch MP, Pan Q. Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation. Liver Transpl 2014; 20: 261-269 [PMID: 24376158 DOI: 10.1002/lt.23806].
103. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, Bernard PH, Boillot O, Compagnon P, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouillères O, Cherqui D, Duvoux C. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006; 12: 7319-7325 [PMID: 17143948].
104. Lee JY, Kim YH, Yi NJ, Kim HS, Lee HS, Lee BK, Kim H, Choi YR, Hong G, Lee KW, Suh KS. Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation. Clin Mol Hepatol 2014; 20: 192-203 [PMID: 25032186 DOI: 10.3350/cmh.2014.20.2.192].
105. Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E, Onaca N, Goldstein R, Levy M, Klintmalm GB. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009; 15: 1834-1842 [PMID: 19938137 DOI: 10.1002/lt.21953].
106. Dhawan A. Immunosuppression in pediatric liver transplantation: are little people different?. Liver Transpl 2011; 17 Suppl 3: S13-S19 [PMID: 21850684 DOI: 10.1002/lt.22422].
107. Thangarajah D, O'Meara M, Dhawan A. Management of acute rejection in paediatric liver transplantation. Paediatr Drugs 2013; 15: 459-471 [PMID: 23925711 DOI: 10.1007/s40272-013-0034-4].
108. Al-Sinani S, Dhawan A. Corticosteroids usage in pediatric liver transplantation: To be or not to be! Pediatr Transplant 2009; 13: 160-170 [PMID: 19037913 DOI: 10.1111/j.1399-3046.2008.01043. x].
109. Ludwig J. Classification and terminology of hepatic allograft rejection: whither bound?. Mayo Clin Proc 1989; 64: 676-679 [PMID: 2664363].
110. Höroldt BS, Burattin M, Gunson BK, Bramhall SR, Nightingale P, Hübscher SG, Neuberger JM. Does the Banff rejection activity index predict outcome in patients with early acute cellular rejection following liver transplantation?. Liver Transpl 2006; 12: 1144-1151 [PMID: 16799959 DOI: 10.1002/lt.20779].
111. Volpin R, Angeli P, Galioto A, Fasolato S, Neri D, Barbazza F, Merenda R, Del Piccolo F, Strazzabosco M, Casagrande F, Feltracco P, Sticca A, Merkel C, Gerunda G, Gatta A. Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial. Liver Transpl 2002; 8: 527-534 [PMID: 12037783 DOI: 10.1053/jlts.2002.33456].
112. Wu L, Tam N, Deng R, Wu C, Chen P, Wang D, He X. Steroidresistant acute rejection after cadaveric liver transplantation: experience from one single center. Clin Res Hepatol Gastroenterol 2014; 38: 592-597 [PMID: 24928711 DOI: 10.1016/j. clinre.2014.04.005].
113. Aw MM, Taylor RM, Verma A, Parke A, Baker AJ, Hadzic D, Muiesan P, Rela M, Heaton ND, Mieli-Vergani G, Dhawan A. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. Transplantation 2003; 75: 796-799 [PMID: 12660504 DOI: 10.1097/01.TP.0000054682.53834.EA].
114. Fernandes ML, Lee YM, Sutedja D, Wai CT, Isacc J, Prabhakaran K, Lim SG, Lee KH. Treatment of steroid-resistant acute liver transplant rejection with basiliximab. Transplant Proc 2005; 37: 2179-2180 [PMID: 15964372 DOI: 10.1016/j.transproceed.2005.0 3.030].
115. Orr DW, Portmann BC, Knisely AS, Stoll S, Rela M, Muiesan P, Bowles MJ, Heaton ND, O'Grady JG, Heneghan MA. Antiinterleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation. Transplant Proc 2005; 37: 4373-4379 [PMID: 16387124 DOI: 10.1016/j.transproceed.2005.10.022].
116. Takatsuki M, Uemoto S, Inomata Y, Egawa H, Kiuchi T, Fujita S, Hayashi M, Kanematsu T, Tanaka K. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001; 72: 449-454 [PMID: 11502975].
117. Devlin J, Doherty D, Thomson L, Wong T, Donaldson P, Portmann B, Williams R. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 27: 926-933 [PMID: 9537430 DOI: 10.1002/hep.510270406].
118. Benítez C, Londoño MC, Miquel R, Manzia TM, Abraldes JG, Lozano JJ, Martínez-Llordella M, López M, Angelico R, Bohne F, Sese P, Daoud F, Larcier P, Roelen DL, Claas F, Whitehouse G, Lerut J, Pirenne J, Rimola A, Tisone G, Sánchez-Fueyo A. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013; 58: 1824-1835 [PMID: 23532679 DOI: 10.1002/hep.26426].